Pediatric Obesity: Pharmacotherapy Selector

Step-by-step guide to selecting and initiating pharmacotherapy in children ≥12 years with obesity. All agents must be combined with behavioural and psychological interventions.

Based on CMAJ 2025 Clinical Practice Guideline (Ball et al., doi: 10.1503/cmaj.241456).

---

Step 1 — Confirm Eligibility

Before prescribing, confirm all three:

Check	Criteria
Age	≥ 12 years (no evidence for < 12)
Diagnosis	Obesity confirmed (BMIz using WHO/Canadian charts)
Behavioural program	Currently enrolled or starting alongside medication

⚠️ Pharmacotherapy must always be co-prescribed with behavioural and psychological interventions. Medication alone is not recommended.

---

Step 2 — Assess Contraindications and Preferences

Before selecting an agent, screen for:

• GI conditions (IBD, gastroparesis) — caution with GLP-1RAs
• Eating disorder (binge eating, atypical anorexia) — psychiatric clearance before any pharmacotherapy
• Renal or hepatic impairment — affects metformin dosing
• Family access and affordability — GLP-1RAs are costly; metformin widely available
• Patient/family values — injection vs. oral, frequency, side effect tolerability

---

Step 3 — Select Agent

Option A — GLP-1 Receptor Agonists (Preferred where accessible)

Semaglutide, liraglutide, exenatide Conditional recommendation; very low to low certainty

Best for: Significant BMIz reduction needed; cardiometabolic comorbidities (hypertension, dyslipidaemia, insulin resistance)

Evidence:

• BMIz: small to large reduction (semaglutide has largest effect — very large effect on BMIz; 1 RCT, 201 children aged 12–17)
• HRQoL: small benefit (semaglutide); little/no effect for others
• Triglycerides: large benefit (semaglutide); small for others
• HDL-C, LDL-C, total cholesterol, systolic BP: small benefit (semaglutide)

Common AEs (important — discuss upfront):

• GI: nausea, diarrhea, vomiting, abdominal pain (most common; 79% semaglutide vs. 82% placebo — many are trivial and self-limiting)

Serious AEs (uncertain risk):

• Cholelithiasis, appendicitis (11% semaglutide vs. 9% placebo in key RCT)
• Risk appears similar to control groups but uncertain — monitor

Semaglutide note: Stronger evidence than liraglutide/exenatide based on current data, but guideline recommends GLP-1RAs as a class due to limited paediatric RCTs.

---

Option B — Biguanides (Metformin)

Good first option, especially if GLP-1RAs unavailable or unaffordable Conditional recommendation; low to moderate certainty

Best for: Insulin resistance present; oral route preferred; cost/access barrier to GLP-1RAs

Evidence:

• BMIz: moderate reduction
• Cardiometabolic: small benefits on lipids and insulin resistance
• HRQoL, anxiety, depression: little to no effect

AEs:

• No serious AEs reported in paediatric studies
• Mild-moderate GI (nausea, diarrhea) — more than placebo but manageable; start low and titrate
• Not associated with increased serious AEs (critical safety advantage over GLP-1RAs)

---

Option C — Lipase Inhibitors (Orlistat)

Use only if A and B are unavailable or contraindicated Conditional recommendation; low certainty — least preferred

Evidence: Lacks evidence on HRQoL, depression, anxiety.

AEs:

• More serious AEs than control (critically important — higher risk)
• More mild-moderate GI AEs (oily stools, faecal urgency, leakage)
• Fat-soluble vitamin malabsorption — supplement required

⚠️ Avoid as first choice. Only use if GLP-1RAs and metformin are not feasible.

---

Step 4 — Initiate and Counsel

Before prescribing, cover all three with the child and family:

1. Expected benefits: BMIz reduction is likely modest in most (not guaranteed); improvements in cardiometabolic markers; possibly HRQoL
2. Expected harms: Discuss the relevant AE profile for the chosen agent
3. Duration: Obesity is chronic — medication may be long-term; reassess regularly
4. What to do if GI side effects occur: Reassure most are transient; hydration; dose titration strategy

---

Step 5 — Monitoring Plan

Review at 3 months, then every 6 months:

Outcome	Why
BMIz	Primary efficacy marker
HRQoL (PedsQL or similar)	Critically important to families
Depression & anxiety screening	Critically important — monitor throughout
BP (systolic and diastolic)	Cardiometabolic target
Fasting lipids (total cholesterol, LDL-C, HDL-C, TG)	Cardiometabolic benefit expected
Fasting insulin / HOMA-IR	Insulin resistance marker
ALT	Hepatic safety (especially GLP-1RAs)
GI adverse events	Adherence-limiting; especially GLP-1RAs
Serious AEs (hospitalisation)	Especially cholelithiasis with GLP-1RAs

---

Clinical Guardrails

• No pharmacotherapy under 12 years — no evidence base; do not extrapolate
• Always combine with behavioural program — medication alone is not guideline-concordant
• Screen for eating disorders before starting — pharmacotherapy may worsen body image disturbance
• Shared decision-making is mandatory — especially given low-to-moderate certainty evidence for all agents
• Discontinue if no benefit after adequate trial (typically 3–6 months) and reassess
• GLP-1RAs are not stepwise — can be offered alongside or before trying metformin based on clinical picture and family preference

---

Source

CMAJ 2025 Clinical Practice Guideline: Managing obesity in children. Ball GDC et al. CMAJ 2025 April 14; 197:E372–89. doi: 10.1503/cmaj.241456 Updated version: June 3, 2025.